Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial

American Journal of Gastroenterology

Volumn 96, Issue 3, 2001, Pages 656-665

  Richter, Joel E ^a   Kahrilas, Peter J ^b   Johanson, John ^b   Maton, Paul ^b   Breiter, Jeffrey R ^b   Hwang, Clara ^b   Marino, Victoria ^b   Hamelin, Bernard ^b   Levine, Jeffrey G ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EROSIVE GASTRITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; WOUND HEALING;

ADULT; AGED; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; ISOMERISM; MALE; MIDDLE AGED; OMEPRAZOLE; SAFETY; TREATMENT OUTCOME;

EID: 0035071459     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)02393-5     Document Type: Article

References (32)

1. Epidemiology and natural history of gastrooesophageal reflux disease
2. Current diagnosis and treatment of gastroesophageal reflux disease
3. Gastroesophageal reflux disease
4. The Second Canadian Gastroesophageal Reflux Disease Consensus: Moving forward to new concepts
5. Medical treatment of gastroesophageal reflux in the managed care environment
6. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment: Suggested disease management guidelines
7. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease
8. The pathogenesis of gastroesophageal reflux disease: The relationship between epithelial defense, dysmotility, and acid exposure
9. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis
10. Are esophageal symptoms reflux-related? A study of different scoring systems in a cohort of patients with heartburn
11. Critical issues in the management of gastroesophageal reflux disease
12. Progress with proton pump inhibition
13. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: A systematic overview
14. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. Multicenter Study
15. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis
16. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole
17. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: A European multicentre study
18. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: A European multicentre study
19. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: A long-term comparative study
20. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis
21. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux disease
22. Esomeprazole 40 mg provides more effective acid control than omeprazole 40 mg
23. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomised controlled trial
24. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification
25. The endoscopic assessment of esophagitis: A progress report on observer agreement
26. An evidence-based appraisal of reflux disease management - The Gerval Workshop Report
27. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole
28. Rapid symptom relief in reflux oesophagitis: A comparison of lansoprazole and omeprazole
29. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial
30. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesoph agitis grade II, III and IVa (a Dutch multicentre trial)
31. A comparison of omeprazole MUPS 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in the treatment of reflux oesophagitis: A multicenter trial
32. Are there any differences in symptom relief and healing esophagitis between proton pump inhibitors (PPIs): A meta-analysis of comparative trials